ProfileGDS5678 / 1457322_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 83% 81% 82% 80% 80% 86% 84% 82% 81% 80% 82% 81% 80% 82% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.0113283
GSM967853U87-EV human glioblastoma xenograft - Control 25.8689581
GSM967854U87-EV human glioblastoma xenograft - Control 35.9007782
GSM967855U87-EV human glioblastoma xenograft - Control 45.842180
GSM967856U87-EV human glioblastoma xenograft - Control 55.7454580
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.2608586
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.9999884
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.9589582
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.7570481
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.74480
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.8548582
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.7872481
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.7022880
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.8580482